Literature DB >> 27425379

Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries.

Erkan Elci1, Cihan Kaya2, Numan Cim3, Recep Yildizhan3, Gulhan Gunes Elci3.   

Abstract

OBJECTIVE: To compare cardiac risk markers such as asymmetric dimethyl arginine (ADMA), C-reactive protein (CRP), homocystein (Hcy), plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF), angiopoietin-related growth factor 6 (ANGPTL6) in obese and non-obese patients with polycystic ovary syndrome (PCOS). STUDY
DESIGN: Thirty obese (BMI >30 kg/m2) and 30 non-obese (BMI < 30 kg/m2) patients diagnosed with PCOS and 30 age-matched healthy controls were included in the study. The ages of subjects were varying between 18 and 30 years. Serum ADMA, CRP, Hcy, PAI-1, VEGF and ANGPTL6 levels were analyzed for each subject.
RESULTS: Serum ADMA, CRP, Hcy, PAI-1, VEGF and ANGPTL6 levels were significantly elevated in obese and non-obese women with PCOS in comparison to control subjects (p < 0.05). This elevation was more obvious in the obese PCOS group than in the other group.
CONCLUSIONS: Cardiovascular risk markers such as ADMA, CRP, Hcy, PAI-1, VEGF and ANGPTL6 levels are elevated in women with PCOS.

Entities:  

Keywords:  Angiopoietin-related growth factor; cardiovascular diagnostic technic; obesity; polycystic ovary syndrome

Mesh:

Substances:

Year:  2016        PMID: 27425379     DOI: 10.1080/09513590.2016.1203893

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  6 in total

1.  Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers.

Authors:  Sonali S Patel; Uyen Truong; Martina King; Annie Ferland; Kerrie L Moreau; Jennifer Dorosz; John E Hokanson; Hong Wang; Gregory L Kinney; David M Maahs; Robert H Eckel; Kristen J Nadeau; Melanie Cree-Green
Journal:  Vasc Med       Date:  2017-01-17       Impact factor: 3.239

2.  Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update.

Authors:  Subeka Abraham Gnanadass; Yogamaya Divakar Prabhu; Abilash Valsala Gopalakrishnan
Journal:  Arch Gynecol Obstet       Date:  2021-01-13       Impact factor: 2.344

3.  Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.

Authors:  U Durmus; C Duran; S Ecirli
Journal:  J Endocrinol Invest       Date:  2016-11-12       Impact factor: 4.256

4.  C-Reactive Protein, Fibrinogen, Leptin, and Adiponectin Levels in Women with Polycystic Ovary Syndrome.

Authors:  Cagdas Ozgokce; Erkan Elci; Recep Yildizhan
Journal:  J Obstet Gynaecol India       Date:  2020-08-19

5.  Expression of Serum Omentin, CTRP9, and Vaspin in Patients with Polycystic Ovary Syndrome.

Authors:  Yuhong Wang; Ning Liu; Jing Lu; Liping Yang; Changyan Wang; Jing Chen; Wenliang Chang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-17       Impact factor: 2.650

6.  Homocysteine level, body mass index and clinical correlates in Chinese Han patients with schizophrenia.

Authors:  Yuanyuan Huang; Kai Wu; Hehua Li; Jing Zhou; Dongsheng Xiong; Xia Huang; Jiahui Li; Ya Liu; Zhilin Pan; David T Mitchell; Fengchun Wu; Xiang Yang Zhang
Journal:  Sci Rep       Date:  2020-09-30       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.